# Evaluation of Adhesion and Dermal Tolerability of EMSAM

> **NCT00531596** · PHASE4 · COMPLETED · sponsor: **Somerset Pharmaceuticals** · enrollment: 300 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** EMSAM (Selegiline Transdermal System) 6mg/24Hr
- **DRUG:** EMSAM (Selegiline Transdermal System) 9mg/24Hr
- **DRUG:** EMSAM (Selegiline Transdermal System) 12mg/24hr

## Key facts

- **NCT ID:** NCT00531596
- **Lead sponsor:** Somerset Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** —
- **Final completion:** 2007-07
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2007-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00531596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00531596, "Evaluation of Adhesion and Dermal Tolerability of EMSAM". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00531596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*